-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Upgrades Edwards Lifesciences to Buy, Raises Price Target to $113

Benzinga·11/04/2026 10:00:07
Truist Securities analyst Richard Newitter upgrades Edwards Lifesciences (NYSE:EW) from Hold to Buy and raises the price target from $95 to $113.